Open access · US-GOV
via ClinicalTrials.gov Clinical trial
mtDNA Damage in Alzheimer's Disease (AD)
Authors not listed
Duke University · 2018
Abstract
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2018). mtDNA Damage in Alzheimer's Disease (AD). <em>Duke University</em>. https://clinicaltrials.gov/study/NCT03340571
Vancouver
Anonymous. mtDNA Damage in Alzheimer's Disease (AD). Duke University. 2018.
BibTeX
@misc{anon2018mtDNAD,
title = {mtDNA Damage in Alzheimer's Disease (AD)},
author = {Anonymous},
journal = {Duke University},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature Reviews Neurology 2024
Preprint · OA
Is Alzheimer disease a disease?
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
medRxiv 2026
Open access · OA
Alzheimer’s disease blood biomarkers reveal proteomic modules of disease progression
Cell Death and Differentiation 2008
Citation only
Astroglia in dementia and Alzheimer's disease
Peking University First Hospital 2024
Open access · US-GOV